December 11, 2017 09:29 AM EST

Hookipa raises $60M to fund immunotherapy R&D; Roche bags Ionis option for $45M; Regeneron fights back against Novartis' Eylea rival

Amber Tong

→ Hookipa Biotech has raised $60 million (€50 million) in an oversubscribed Series C round to help push its lead program, a vaccine for infections …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hookipa raises $60M to fund immunotherapy R&D; Roche bags Ionis option for $45M; Regeneron fights back against Novartis' Eylea rival

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Hookipa rais­es $60M to fund im­munother­a­py R&D; Roche bags Io­n­is op­tion for $45M; Re­gen­eron fights back against No­var­tis' Eylea ri­val

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Hookipa raises $60M to fund immunotherapy R&D; Roche bags Ionis option for $45M; Regeneron fights back against Novartis' Eylea rival

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA